BCM
OBIO icon

Boxer Capital Management’s Orchestra BioMed OBIO Stock Holding History

Boxer Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-238,193
Closed -$953K – 46
2024
Q4 		$953K Buy
+238,193
New +$1.28M 0.08% 53

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Boxer Capital Management's OBIO Position: Q1 2025 in Review

Boxer Capital Management sold out of Orchestra BioMed (OBIO) in Q1 2025, closing a stake of 238,193 shares — an estimated $953K sold.

Boxer Capital Management first reported a position in OBIO in Q4 2024 and held it in 1 quarter. The position peaked at $953K in Q4 2024. 56 funds tracked by Wall St. Rank hold OBIO as of Q1 2025.

  • Boxer Capital Management reported no remaining Orchestra BioMed position as of Q1 2025 after selling out during the quarter.
  • Boxer Capital Management sold 238,193 Orchestra BioMed shares in Q1 2025, an estimated $953K.
  • Boxer Capital Management first reported a position in Orchestra BioMed in Q4 2024 and held it in 1 quarter.
  • Boxer Capital Management's Orchestra BioMed position peaked at $953K in Q4 2024.
  • 56 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2025.

Based on Boxer Capital Management's 13F filing for Q1 2025, filed 15 May 2025.